# Peter Sever

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/peter-sever/

## Facts

| Field | Value |
| --- | --- |
| Citations | 48,576 |
| Field | Blood Pressure and Hypertension Studies |
| h-index | 80 |
| i10-index | 193 |
| Last Known Institution | Lung Institute |
| OpenAlex ID | https://openalex.org/A5111847356 |
| Works | 341 |

## Researcher papers

- [Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease](https://scholariq.org/papers/evolocumab-and-clinical-outcomes-in-patients-with-cardiovascular-disease/)
- [Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial](https://scholariq.org/papers/prevention-of-coronary-and-stroke-events-with-atorvastatin-in-hypertensive/)
- [Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial](https://scholariq.org/papers/prevention-of-cardiovascular-events-with-an-antihypertensive-regimen-of/)
- [Interpretation of the evidence for the efficacy and safety of statin therapy](https://scholariq.org/papers/interpretation-of-the-evidence-for-the-efficacy-and-safety-of-statin-therapy/)
- [Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension](https://scholariq.org/papers/prognostic-significance-of-visit-to-visit-variability-maximum-systolic-blood/)
- [Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial](https://scholariq.org/papers/spironolactone-versus-placebo-bisoprolol-and-doxazosin-to-determine-the-optimal/)
- [British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary](https://scholariq.org/papers/british-hypertension-society-guidelines-for-hypertension-management-2004-bhs-iv/)
- [Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies](https://scholariq.org/papers/endocrine-and-haemodynamic-changes-in-resistant-hypertension-and-blood-pressure/)

## Researcher topics

- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Genetic Associations and Epidemiology](https://scholariq.org/topics/genetic-associations-and-epidemiology/)
- [Hormonal Regulation and Hypertension](https://scholariq.org/topics/hormonal-regulation-and-hypertension/)
- [Sodium Intake and Health](https://scholariq.org/topics/sodium-intake-and-health/)

## Researcher university

- [Lung Institute](https://scholariq.org/institutions/lung-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.